Literature DB >> 17522329

Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate.

April F Eichler1, Tracy T Batchelor, John W Henson.   

Abstract

Methotrexate (MTX) is a widely used chemotherapeutic agent that can cause acute, subacute, and chronic neurological complications. Subacute MTX neurotoxicity is manifest by abrupt onset of focal cerebral dysfunction occurring days to weeks after MTX administration, usually in children. We describe the neuroimaging features of an adult patient with primary CNS lymphoma who presented with transient aphasia and right hemiparesis 12 days after receiving intravenous high-dose MTX (8 g/m2) chemotherapy. Imaging within 1 h of symptom onset showed bilateral symmetrical restricted diffusion involving white matter of the cerebral hemispheres. CT angiogram and dynamic susceptibility MRI showed no evidence of vasospasm or perfusion defect. MRI five days later showed near-complete resolution of the abnormalities. MRI 3(1/2) months later showed normal diffusion but new hyperintense T2-weighted signal changes in the subcortical white matter corresponding to previous areas of restricted diffusion. The absence of vascular or perfusion abnormalities suggests that transient cytotoxic edema in white matter may explain the syndrome of subacute MTX neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17522329      PMCID: PMC1907407          DOI: 10.1215/15228517-2007-015

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  24 in total

1.  Transient encephalopathy following high-dose methotrexate.

Authors:  Anselm C W Lee; C H Li; Y C Wong
Journal:  Med Pediatr Oncol       Date:  2003-07

2.  Diffusion-weighted MRIs in an acute leukoencephalopathy following intrathecal chemotherapy.

Authors:  Sonn-Tae Lee; Manho Kim
Journal:  Neurology       Date:  2004-03-09       Impact factor: 9.910

3.  Reversible acute methotrexate leukoencephalopathy: atypical brain MR imaging features.

Authors:  France Ziereisen; Bernard Dan; Nadira Azzi; Alina Ferster; Nash Damry; Catherine Christophe
Journal:  Pediatr Radiol       Date:  2005-12-21

4.  Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma.

Authors:  J C Allen; G Rosen
Journal:  Ann Neurol       Date:  1978-05       Impact factor: 10.422

5.  Neurotoxicity of intrathecal methotrexate: MR imaging findings.

Authors:  Claudio Sandoval; Martin Kutscher; Somasundaram Jayabose; Michael Tenner
Journal:  AJNR Am J Neuroradiol       Date:  2003-10       Impact factor: 3.825

6.  White matter and cerebral metabolite changes in children undergoing treatment for acute lymphoblastic leukemia: longitudinal study with MR imaging and 1H MR spectroscopy.

Authors:  Winnie C W Chu; Ki-Wai Chik; Yu-Leung Chan; David K W Yeung; Derek J Roebuck; Robert G Howard; Chi-Kong Li; Constantine Metreweli
Journal:  Radiology       Date:  2003-10-23       Impact factor: 11.105

7.  Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm.

Authors:  R D Henderson; T Rajah; A J Nicol; S J Read
Journal:  Neurology       Date:  2003-01-28       Impact factor: 9.910

8.  High dose systemic methotrexate-associated acute neurologic dysfunction.

Authors:  R J Packer; R I Grossman; J B Belasco
Journal:  Med Pediatr Oncol       Date:  1983

9.  Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery.

Authors:  G Rosen; R C Marcove; B Caparros; A Nirenberg; C Kosloff; A G Huvos
Journal:  Cancer       Date:  1979-06       Impact factor: 6.860

10.  Neurologic sequelae of methotrexate and ionizing radiation: a new classification.

Authors:  W A Bleyer
Journal:  Cancer Treat Rep       Date:  1981
View more
  7 in total

1.  Hyperperfusion on magnetic resonance imaging in acute chemotherapy-related leukoencephalopathy.

Authors:  Lisa Michael El-Hakam; Melissa Beth Ramocki; James John Riviello; Anna Illner
Journal:  J Child Neurol       Date:  2010-04-02       Impact factor: 1.987

2.  Magnetization transfer imaging provides no evidence of demyelination in methotrexate-induced encephalopathy.

Authors:  F R Miese; F R Schuster; K Pierstorff; M Karenfort; H J Laws; A Borkhardt; A Saleh
Journal:  AJNR Am J Neuroradiol       Date:  2010-07-22       Impact factor: 3.825

3.  [Hemiparesis in acute lymphoblastic leukemia].

Authors:  M Karremann; G von Komorowski; E Neumaier-Probst; M Dürken
Journal:  Radiologe       Date:  2010-08       Impact factor: 0.635

Review 4.  Metabotropic glutamate receptors in cancer.

Authors:  Lumeng J Yu; Brian A Wall; Janet Wangari-Talbot; Suzie Chen
Journal:  Neuropharmacology       Date:  2016-02-16       Impact factor: 5.250

Review 5.  Concomitant rheumatoid arthritis and amyotrophic lateral sclerosis: report of two new cases and review of literature.

Authors:  Melissa Padovan; Luisa Maria Caniatti; Francesco Trotta; Marcello Govoni
Journal:  Rheumatol Int       Date:  2011-01-22       Impact factor: 2.631

6.  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

Authors:  Anwar R Padhani; Guoying Liu; Dow Mu Koh; Thomas L Chenevert; Harriet C Thoeny; Taro Takahara; Andrew Dzik-Jurasz; Brian D Ross; Marc Van Cauteren; David Collins; Dima A Hammoud; Gordon J S Rustin; Bachir Taouli; Peter L Choyke
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

7.  Stroke-like encephalopathy following high-dose intravenous methotrexate in an adolescent with osteosarcoma: a case report.

Authors:  Daniel Almeida do Valle; Fabiana Maria Kakehasi; Roberta Maria Pereira Albuquerque de Melo; Claudia Machado Siqueira; Thaiane Ferreira Soares; Karla Emilia de Sá Rodrigues
Journal:  Rev Bras Hematol Hemoter       Date:  2016-10-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.